Joe Costa

Medical Brief: PIK3CA and KRAS Mutations Predict for Response to Everolimus Therapy

August 02, 2021

Medical Brief: Histiocytic Sarcoma

July 26, 2021

Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib

July 12, 2021

An Interview with Scientific Advisory Board Member: Dr. Corrie Painter

June 30, 2021

Topics

One post • COO of Wedgewood Pharmacy

Featuring

Dr. Gerry Post, The Internet

Joe Costa, COO of Wedgewood Pharmacy

Compounding Pharmaceuticals in the Age of COVID-19, Part 2

In our fifth webinar of this series, we welcome Joe Costa, COO of Wedgewood Pharmacy, to discuss the effects of the COVID-19 pandemic on the veterinary compounding pharmaceutical industry.

Dr. Gerry Post Joe Costa

Apr 23 • 7 min read

Discover more content...

Enter some keywords in the search box above, we will do our best to offer you relevant results.

Results

We're sorry!

We couldn't find any results for your search. Please try again with another keywords.

Success! Your account is fully activated, you now have access to all content.

Recent articles

Medical Brief: PIK3CA and KRAS Mutations Predict for Response to Everolimus Therapy

Medical Brief: Histiocytic Sarcoma

Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib

An Interview with Scientific Advisory Board Member: Dr. Corrie Painter

Topics

Joe Costa

Compounding Pharmaceuticals in the Age of COVID-19, Part 2

Discover more content...

Results

We're sorry!

Recent articles

Medical Brief: PIK3CA and KRAS Mutations Predict for Response to Everolimus Therapy

Medical Brief: Histiocytic Sarcoma

Medical Brief: Treatment of Canine Cutaneous Epitheliotropic T-cell lymphoma with Olacitinib

An Interview with Scientific Advisory Board Member: Dr. Corrie Painter

Topics